CYD-2-11

• Description:

  CYD-2-11 is a selective Bax agonist with a Ki value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC50 values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer[1][2].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cyd-2-11.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NCCOC1=CC=CC=C1/C=C2C3=C(C=CC([N+]([O-])=O)=C3)C4=C/2C=CC=C4

• Molecular Formula:

  C22H18N2O3

• Molecular Weight:

  358.39

• References & Citations:

  [1]Liu G, et al. Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer. Eur J Med Chem. 2019 Sep 15;178:589-605.|[2]Li R, et al. Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Res. 2017 Jun 1;77 (11) :3001-3012. doi: 10.1158/0008-5472.CAN-16-2356. Epub 2017 Apr 5.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1425944-22-4]